Story

Eli Lilly's Oral Weight-Loss Drug Foundayo Gains First European Approval in UK

ENTHMSVIIDZHZH-TWJAKOHI
Aug 10, 20261 min read
Eli Lilly's Oral Weight-Loss Drug Foundayo Gains First European Approval in UK
Text size
Background

Eli Lilly's (NYSE: LLY) oral medication Foundayo has been authorized for weight management and type 2 diabetes by Britain’s medicines regulator, making the UK the first European country to approve the treatment. The news boosted the company's shares, which were up more than 3% in afternoon trading on Monday.

UK Authorization and Launch

The Medicines and Healthcare products Regulatory Agency (MHRA) confirmed the approval but noted the drug's immediate availability is limited. "Whilst this tablet is approved for use in the UK, it is not available currently via the NHS," the agency stated.

According to a company spokesperson who spoke to Reuters, Eli Lilly plans to launch Foundayo in the UK later this month through private prescription. The spokesperson added that the pill's private list price would be lower than its injectable drug Mounjaro, which costs £399 for a month's supply, but did not provide specific pricing details.

Sample IUX Markets – In-articleAd

Competitive Landscape

The approval intensifies the competition between Eli Lilly and rival Novo Nordisk (NYSE: NVO) in the rapidly growing market for weight-loss therapies, which is increasingly expanding from injectable treatments to oral alternatives. While injectables still dominate the market, pills are gaining significant traction among patients.

Foundayo, a once-daily GLP-1 tablet, holds a key convenience advantage over its primary oral competitor. According to the report, Foundayo can be taken without restrictions on food or water. This contrasts with Novo Nordisk's Wegovy pill, which requires patients to take it on an empty stomach and wait 30 minutes before consuming food, beverages, or other medications.

Read next

More on Stocks
Back to latest news

LATEST